Raffles Medical Group Ltd
Raffles Medical Group Ltd Fundamental Analysis
Raffles Medical Group Ltd (BSL.SI) shows weak financial fundamentals with a PE ratio of 39.13, profit margin of 8.38%, and ROE of 4.62%. The company generates $0.6B in annual revenue with moderate year-over-year growth of 6.15%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 42.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BSL.SI's fundamental strength across five key dimensions:
Efficiency Score
WeakBSL.SI struggles to generate sufficient returns from assets.
Valuation Score
WeakBSL.SI trades at a premium to fair value.
Growth Score
ModerateBSL.SI shows steady but slowing expansion.
Financial Health Score
ExcellentBSL.SI maintains a strong and stable balance sheet.
Profitability Score
WeakBSL.SI struggles to sustain strong margins.
Key Financial Metrics
Is BSL.SI Expensive or Cheap?
P/E Ratio
BSL.SI trades at 39.13 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BSL.SI's PEG of 22.04 indicates potential overvaluation.
Price to Book
The market values Raffles Medical Group Ltd at 1.77 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 23.21 times EBITDA. This signals the market has high growth expectations.
How Well Does BSL.SI Make Money?
Net Profit Margin
For every $100 in sales, Raffles Medical Group Ltd keeps $8.38 as profit after all expenses.
Operating Margin
Core operations generate 10.88 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.62 in profit for every $100 of shareholder equity.
ROA
Raffles Medical Group Ltd generates $3.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Raffles Medical Group Ltd produces operating cash flow of $81.94M, showing steady but balanced cash generation.
Free Cash Flow
Raffles Medical Group Ltd generates strong free cash flow of $75.34M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.04 in free cash annually.
FCF Yield
BSL.SI converts 4.07% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
39.13
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
22.04
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.77
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.26
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.08
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How BSL.SI Stacks Against Its Sector Peers
| Metric | BSL.SI Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 39.13 | 28.31 | Worse (Expensive) |
| ROE | 4.62% | 699.00% | Weak |
| Net Margin | 8.38% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.08 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 1.31 | 2775.16 | Neutral |
| ROA | 3.35% | -14469.00% (disorted) | Weak |
BSL.SI outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Raffles Medical Group Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
40.54%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
0.81%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
-24.24%
Industry Style: Defensive, Growth, Innovation
Declining